Andreas Saltos, MD, discusses final results from a phase 2 trial of first-line pembrolizumab plus vorinostat in patients with metastatic non–small cell lung cancer.
Andreas Saltos, MD
Advertisement
Articles by Andreas Saltos, MD
Andreas Saltos, MD, discusses the importance of broad molecular testing in non–small cell lung cancer.
Advertisement
Latest Updated Articles
Dr. Saltos on the Importance of Broad Molecular Testing in NSCLCApril 30th 2021
Advertisement
Advertisement
Trending on OncLive
1
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
2
Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg
3
Retrospective Data Show Zanubrutinib May Less AFib Burden in Real-World CLL
4
Dato-DXd Hits Key Secondary Efficacy End Points in First-Line TNBC
5